ENO3

Across TCGA pan-cancer cohorts, ENO3 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated ENO3 data layer compared with 25 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher ENO3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ENO3 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

BRCA, STAD, and BLCA are the cancer types where ENO3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	OS	Median	All	0.287	0.924	<.001	36	view →
STAD	OS	Median	All	0.184	0.730	.001	18	view →
BLCA	OS	Median	All	0.090	0.688	<.001	18	view →
SCLC	OS	Median	All	0.055	0.708	<.001	12	view →
LUAD	OS	Median	All	0.258	0.787	.018	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
SKCM	DFS	Median	II,III,IV	1.000	0.682	.033	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

ENO3–BRCA (OS)

Open the BRCA breakdown →